|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00950 LEE'S PHARM
Nominal 
1.220 +0.020 (+1.667%) | 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Turnover | 1,053,034 | -14.606% | 1,233,148 | 1,266,157 | 1,216,716 | 1,218,913 |
| Cost of Sales | (501,723) | 8.506% | (462,393) | (459,873) | (435,650) | (420,657) |
| Gross Profit | 551,311 | -28.471% | 770,755 | 806,284 | 781,066 | 798,256 |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | (90,284) | (1,180) | (73) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (870) | -21.196% | (1,104) | (3,495) | (11,414) | (11,895) | |
| Profit / (Loss) before Taxation | 30,785 | -54.635% | 67,861 | 1,969,366 | 134,037 | 122,886 | |
| Taxation | (10,836) | -50.804% | (22,026) | (9,482) | (55,503) | (59,541) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (3,251) | -- | 5,449 | 27,292 | 50,782 | 62,208 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 16,698 | -67.440% | 51,284 | 1,987,176 | 129,316 | 125,553 | |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Net Finance Costs / (Income) | 10,364 | 99.231% | 5,202 | (190) | (2,600) | (4,392) |
| Depreciation & Amortisation | 149,501 | -1.966% | 152,499 | 146,867 | 127,504 | 94,142 |
| Directors' Emoluments | 32,861 | 220.158% | 10,264 | 92,625 | 48,115 | 49,952 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 2.840 | -67.394% | 8.710 | 337.580 | 21.990 | 21.220 |
| DPS (cts) | 1.800 | -- | 2.000 | 6.100 | 5.800 | 5.600 |
| Dividend Payout Ratio (%) | 63.380% | -- | 22.962% | 1.807% | 26.376% | 26.390% |
| Cash flow per share ($) | 0.187 | -- | 0.482 | 0.358 | 0.372 | 0.676 |
| NBV per share ($) | 3.463 | -- | 3.268 | 4.186 | 3.655 | 3.905 |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD 62,478,000 |
| %Change | 287.653% |
| EPS / (LPS) | HKD 0.106 |
| NBV Per Share ($) | HKD 2.910 |